Showing 120 of 120on this page. Filters & sort apply to loaded results; URL updates for sharing.120 of 120 on this page
InflaRx logo in transparent PNG and vectorized SVG formats
InflaRx Presents New Preclinical Findings for INF904 at the
Analysts Set InflaRx N.V. (NASDAQ:IFRX) PT at $7.50 - American Market News
InflaRx Cuts Costs: 30% Workforce Reduction and Shift in Focus ...
InflaRx Ends Lead Asset Development After Failed Study For Rare And ...
InflaRx Announces Topline Phase 2a Data for INF904 Trial
InflaRx plans to launch Covid antibody with five-figure price tag
InflaRx Announces Decision to Enter Phase III Development of IFX‑1 in ...
Inflarx (IFRX) Investor Presentation - Slideshow (NASDAQ:IFRX ...
InflaRx secures European Commission approval for ARDS drug - European ...
InflaRx wins EU approval for Gohibic in Covid-19-induced ARDS
InflaRX jumps 60% On FDA emergency approval of Gohibic for Covid-19 ...
InflaRx Targets Uncommon Skin Disorder Research Following Underwhelming ...
InflaRx to Reveal Phase 2a Clinical Trial Data Amid Q3 2025 Financials
InflaRx Profile | The Scientist
InflaRX raises US$55m in Series D round - European Biotechnology Magazine
InflaRx Aktie: Neueste Updates und Analysen ( Aktualisiert Mai 2026 )
InflaRx Aktie: Kampf ums Überleben an der Nasdaq
InflaRx to Announce Phase 2a INF904 Data in HS and CSU Nov 10 | IFRX ...
InflaRx Aims for $100M IPO to Support Anti-Inflammatory Drug Development
InflaRx Reports Phase 2a: 63% HiSCR50 in HS, UAS7 -13.7 | IFRX Stock News
InflaRx N.V. (IFRX) Stock Price, Quote, News & Analysis | Seeking Alpha
InflaRx Announces Top-Line SHINE Phase IIb Results for
InflaRx Advances INF904 for CSU and HS with Phase 2a Study ...
InflaRx Set to Reveal 2024 Results and Join Investor Events - Investors ...
The InflaRx Commitment
InflaRx (IFRX) Skyrockets 110% in Six Months: Here's Why
InflaRx N.V. (IFRX) 5.6% in After-hours: What’s Driving the Move?
Inflarx N.V. (IFRX) Stock: Climbs 2.5% Ahead of Key Phase 2a Data Release
InflaRx Provides Update on Phase 3 Data Analyses for Vilobelimab in ...
InflaRx targets key data readouts for INF904 in skin conditions ...
InflaRx (IFRX) Stock Price & Overview
InflaRx (IFRX) Stock Up on FDA's EUA for COVID-19 Treatment
InflaRx Axes Rare Skin Disease Study on Disappointing Late-Stage Data ...
InflaRx (IFRX) details Phase 3 post-hoc data in PG | IFRX Stock News
InflaRx (IFRX) Stock price today - quote & chart
InflaRx Aktie: Explosiver Wochenabschluss!
InflaRx Announces Positive Phase 2a Results for INF904 in HS and CSU ...
InflaRx (IFRX) Is Up 17.7% After INF904 Shows Promising Results in ...
InflaRx Aktie: News und Prognose
InflaRx today announced that the Company will publish its financial and ...
Why InflaRx N.V. Stock Is Poised For A Rebound?
InflaRx (IFRX) Turns All-In on Izicopan—Catalyst Looms as Binary Make ...
InflaRx Plummets 60%: A Deep Dive into the Technical Sell-Off
Is InflaRx NV Gaining or Losing Market Support? - InflaRx (NASDAQ:IFRX ...
InflaRx Provides Update on Phase 3 Data Analyses for
InflaRx (IFRX.O) Surges 20.5% Amid Mixed Technical Signals and Sector ...
InflaRx may find path forward for COVID drug in skin disorder
InflaRx Navigates Clinical Crossroads: Can Upcoming Data Turn the Tide?
InflaRx will attend the upcoming EADV Congress, one of the leading ...
InflaRx Prepares for Key Phase 2a Clinical Trial Results
InflaRx Discontinues Pyoderma Gangrenosum Trial, Shifts Focus to INF904 ...
InflaRx Stock: Late Entrant Into The Covid Space (NASDAQ:IFRX ...
InflaRx Stock: Gohibic Flops, INF904 Underwhelms, Cash Burn Accelerates ...
InflaRx announces a $55M Series D financing and investment round to ...
InflaRX | Bain Capital Life Sciences
InflaRx N.V. (IFRX) Discusses Topline Phase 2a Data in Chronic ...
InflaRx Announces Pricing of Initial Public Offering - European ...
InflaRx Aktie: Entscheidungswoche steht bevor
InflaRx cans Gohibic development after skin disease trial stopped for ...
InflaRx Aktie: Alles auf Izicopan
InflaRx reveals phase 3 post‑hoc efficacy signals for vilobelimab in ...
InflaRx N.V. - InflaRx - virtual R&D event INF904: oral C5aR inhibitor ...
InflaRx anuncia una profunda reestructuración, con despidos del 30% de ...
InflaRx Halts Development of Gohibic: What You Need to Know About the ...
InflaRx | LinkedIn
BioCentury - Inflarx drops lead program targeting C5a in rare skin disorder
InflaRx N.V. will participate in the Guggenheim SMID Cap Biotech… | InflaRx
InflaRx (IFRX) cuts 30% of staff, extends cash runway to 2027 | IFRX ...
InflaRx Aktie: Orale Wirkstoffe priorisiert
Exploring InflaRx N.V. (IFRX): Who s Buying and Why? – DCFmodeling.com
InflaRx N.V. - AnnualReports.com
Inflarx flexes; HS, CSU continue to percolate | BioWorld
InflaRx Aktie: Warten auf die große Wende?
InflaRx completes enrolment in Phase IIb hidradenitis suppurativa trial
InflaRx Aktie: Vertrauenskrise oder Neustart?
InflaRx presents new preclinical findings for INF904
InflaRx reports positive phase 2 results for HS and CSU treatments - PMLiVE
InflaRx: Neustart mit Hindernissen
Reining in Inflammation to Treat ARDS | The Scientist
Inflarx-Zulassung: Hoffnung über COVID-19 hinaus
Shares Drop 90% as InflaRx's Antibody for Inflammatory Disease Fails ...
InflaRx: A High-Risk, High-Reward Play on Complement Inhibition in ...
At the 9th Annual Complement-Based Drug Development Summit in Boston ...
Press Releases
InflaRx's Vilobelimab Misses Primary Goal in Phase 3 Skin Disease Trial
InflaRx’s Sudden 14% Drop: What’s Behind the Sharp Intraday Slide?
InflaRx-Aktie +130%: Das steckt dahinter
Taking the fight to inflammatory disease: InflaRx’s first-in-class C5a ...
#nielsriedemann #inflarx #inflammation #complementcomponent5a #sepsis ...
InflaRx, a bm|t Investee-Partner, completed a minimum 75 Mio. USD ...
InflaRx's Mysterious 14% Surge: Unraveling the Technical and Market Drivers
InflaRx's Strategic Pivot: Is the Risk Priced In or the Upside ...
Inflarx-Medikament gegen Covid wird in USA zugelassen | Nau.ch
China’s WuXi Biologics to Make German Biopharma Firm InflaRx’s Covid-19 ...
08-2025-InflaRx Reports Second Quarter 2025 Financial Results and ...
